{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:14:40Z","timestamp":1781100880693,"version":"3.54.1"},"reference-count":212,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T00:00:00Z","timestamp":1350950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s10620-012-2445-4","type":"journal-article","created":{"date-parts":[[2012,10,22]],"date-time":"2012-10-22T09:18:52Z","timestamp":1350897532000},"page":"897-914","source":"Crossref","is-referenced-by-count":120,"title":["Acute and Acute Severe (Fulminant) Autoimmune Hepatitis"],"prefix":"10.1007","volume":"58","author":[{"given":"Albert J.","family":"Czaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,23]]},"reference":[{"key":"2445_CR1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000199332","volume":"34","author":"RM Crapper","year":"1986","unstructured":"Crapper RM, Bhathal PS, Mackay IR, Frazer IH. \u201cAcute\u201d autoimmune hepatitis. Digestion. 1986;34:216\u2013225.","journal-title":"Digestion"},{"key":"2445_CR2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00004836-198906000-00012","volume":"11","author":"JS Amontree","year":"1989","unstructured":"Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol. 1989;11:303\u2013307.","journal-title":"J Clin Gastroenterol"},{"key":"2445_CR3","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0168-8278(94)80251-3","volume":"21","author":"GA Nikias","year":"1994","unstructured":"Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866\u2013871.","journal-title":"J Hepatol"},{"key":"2445_CR4","first-page":"49","volume":"9","author":"Z Michalska","year":"2003","unstructured":"Michalska Z, Radowska D, Staike P, et al. Autoimmune hepatitis in the material of Department and Regional Hospital of Infectious Diseases in Gdansk. Med Sci Monit. 2003;9:49\u201354.","journal-title":"Med Sci Monit"},{"key":"2445_CR5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/qjmed\/hch072","volume":"97","author":"R Ferrari","year":"2004","unstructured":"Ferrari R, Pappas G, Agostinelli D, et al. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the \u201cacute\u201d type. QJM. 2004;97:407\u2013412.","journal-title":"QJM"},{"key":"2445_CR6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00005176-199007000-00027","volume":"11","author":"G Porta","year":"1990","unstructured":"Porta G, Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Pediatr Gastroenterol Nutr. 1990;11:138\u2013140.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2445_CR7","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0168-8278(97)80364-9","volume":"27","author":"D Herzog","year":"1997","unstructured":"Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol. 1997;27:578\u2013582.","journal-title":"J Hepatol"},{"key":"2445_CR8","first-page":"297","volume":"17","author":"EJ Viruet","year":"1998","unstructured":"Viruet EJ, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J. 1998;17:297\u2013300.","journal-title":"P R Health Sci J"},{"key":"2445_CR9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/tropej\/49.6.367","volume":"49","author":"S Aydogdu","year":"2003","unstructured":"Aydogdu S, Ozgenc F, Yurtsever S, et al. Our experience with fulminant hepatic failure in Turkish children: etiology and outcome. J Trop Pediatr. 2003;49:367\u2013370.","journal-title":"J Trop Pediatr"},{"key":"2445_CR10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1542-3565(04)00246-0","volume":"2","author":"WR Kessler","year":"2004","unstructured":"Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625\u2013631.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2445_CR11","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1365-2036.2006.02894.x","volume":"23","author":"Y Miyake","year":"2006","unstructured":"Miyake Y, Iwasaki Y, Terada R, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther. 2006;23:1347\u20131353.","journal-title":"Aliment Pharmacol Ther"},{"key":"2445_CR12","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1007\/s10620-006-9730-z","volume":"52","author":"HM Mudawi","year":"2007","unstructured":"Mudawi HM, Yousif BA. Fulminant hepatic failure in an African setting: etiology, clinical course, and predictors of mortality. Dig Dis Sci. 2007;52:3266\u20133269.","journal-title":"Dig Dis Sci"},{"key":"2445_CR13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00535-010-0316-3","volume":"46","author":"S Yasui","year":"2011","unstructured":"Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46:378\u2013390.","journal-title":"J Gastroenterol"},{"key":"2445_CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1872-034X.2010.00755.x","volume":"41","author":"K Fujiwara","year":"2011","unstructured":"Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults: experience in a Japanese center. Hepatol Res. 2011;41:133\u2013141.","journal-title":"Hepatol Res"},{"key":"2445_CR15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1440-1746.2010.06574.x","volume":"26","author":"M Oketani","year":"2011","unstructured":"Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: a perspective from Japan. J Gastroenterol Hepatol. 2011;26:65\u201371.","journal-title":"J Gastroenterol Hepatol"},{"key":"2445_CR16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1872-034X.2011.00808.x","volume":"41","author":"H Takahashi","year":"2011","unstructured":"Takahashi H, Zeniya M. Acute presentation of autoimmune hepatitis: does it exist? A published work review. Hepatol Res. 2011;41:498\u2013504.","journal-title":"Hepatol Res"},{"key":"2445_CR17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00535-012-0624-x","volume":"47","author":"K Sugawara","year":"2012","unstructured":"Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47:849\u2013861.","journal-title":"J Gastroenterol"},{"key":"2445_CR18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF01071970","volume":"18","author":"GB Goldstein","year":"1973","unstructured":"Goldstein GB, Lam KC, Mistilis SP. Drug-induced active chronic hepatitis. Am J Dig Dis. 1973;18:177\u2013184.","journal-title":"Am J Dig Dis"},{"key":"2445_CR19","first-page":"303","volume":"57","author":"GL Davis","year":"1982","unstructured":"Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF. Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. Mayo Clin Proc. 1982;57:303\u2013309.","journal-title":"Mayo Clin Proc"},{"key":"2445_CR20","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/lt.21036","volume":"13","author":"P Ichai","year":"2007","unstructured":"Ichai P, Duclos-Vallee JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13:996\u20131003.","journal-title":"Liver Transpl"},{"key":"2445_CR21","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1872-034X.2008.00421.x","volume":"38","author":"Y Takikawa","year":"2008","unstructured":"Takikawa Y, Suzuki K. Clinical epidemiology of fulminant hepatitis in Japan. Hepatol Res. 2008;38:S14\u2013S18.","journal-title":"Hepatol Res"},{"key":"2445_CR22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1872-034X.2008.00322.x","volume":"38","author":"K Fujiwara","year":"2008","unstructured":"Fujiwara K, Mochida S, Matsui A, et al. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646\u2013657.","journal-title":"Hepatol Res"},{"key":"2445_CR23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hep.24080","volume":"53","author":"RT Stravitz","year":"2011","unstructured":"Stravitz RT, Lefkowitch JH, Fontana RJ, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011;53:517\u2013526.","journal-title":"Hepatology"},{"key":"2445_CR24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0168-8278(91)90864-8","volume":"13","author":"S Magrin","year":"1991","unstructured":"Magrin S, Craxi A, Fiorentino G, et al. Is autoimmune chronic active hepatitis a HCV-related disease? J Hepatol. 1991;13:56\u201360.","journal-title":"J Hepatol"},{"key":"2445_CR25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0168-8278(05)80279-X","volume":"18","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA, Santrach PJ, et al. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol. 1993;18:342\u2013352.","journal-title":"J Hepatol"},{"key":"2445_CR26","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0016-5085(77)80042-5","volume":"72","author":"WC Maddrey","year":"1977","unstructured":"Maddrey WC, Boitnott JK. Drug-induced chronic liver disease. Gastroenterology. 1977;72:1348\u20131353.","journal-title":"Gastroenterology"},{"key":"2445_CR27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2008-1040723","volume":"1","author":"LB Seeff","year":"1981","unstructured":"Seeff LB. Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis. 1981;1:104\u2013115.","journal-title":"Semin Liver Dis"},{"key":"2445_CR28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","volume":"56","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958\u2013976.","journal-title":"Dig Dis Sci"},{"key":"2445_CR29","first-page":"311","volume":"56","author":"AJ Czaja","year":"1981","unstructured":"Czaja AJ. Current problems in the diagnosis and management of chronic active hepatitis. Mayo Clin Proc. 1981;56:311\u2013323.","journal-title":"Mayo Clin Proc"},{"key":"2445_CR30","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/he.2000.5980","volume":"31","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ, Manns MP, McFarlane IG, Hoofnagle JH. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology. 2000;31:1194\u20131200.","journal-title":"Hepatology"},{"key":"2445_CR31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.20539","volume":"41","author":"AJ Czaja","year":"2005","unstructured":"Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology. 2005;41:207\u2013215.","journal-title":"Hepatology"},{"key":"2445_CR32","first-page":"1","volume":"22","author":"CM Leevy","year":"1976","unstructured":"Leevy CM, Popper H, Sherlock S. Hepatitis. Fogarty Int Proc. 1976;22:1\u201311.","journal-title":"Fogarty Int Proc"},{"key":"2445_CR33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(68)90710-1","volume":"2","author":"J Groote De","year":"1968","unstructured":"De Groote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet. 1968;2:626\u2013628.","journal-title":"Lancet"},{"key":"2445_CR34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/BF01076196","volume":"22","author":"SW Schalm","year":"1977","unstructured":"Schalm SW, Korman MG, Summerskill WH, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis. 1977;22:973\u2013980.","journal-title":"Am J Dig Dis"},{"key":"2445_CR35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00000478-199506000-00010","volume":"19","author":"LJ Burgart","year":"1995","unstructured":"Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol. 1995;19:699\u2013708.","journal-title":"Am J Surg Pathol"},{"key":"2445_CR36","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.2001.03782.x","volume":"96","author":"C Schramm","year":"2001","unstructured":"Schramm C, Kanzler S, zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol. 2001;96:1587\u20131591.","journal-title":"Am J Gastroenterol"},{"key":"2445_CR37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/qjmed\/90.4.289","volume":"90","author":"DR Parker","year":"1997","unstructured":"Parker DR, Kingham JG. Type I autoimmune hepatitis is primarily a disease of later life. QJM. 1997;90:289\u2013296.","journal-title":"QJM"},{"key":"2445_CR38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002512-200825030-00005","volume":"25","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging. 2008;25:219\u2013239.","journal-title":"Drugs Aging"},{"key":"2445_CR39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/0140-6736(90)90870-B","volume":"335","author":"IG McFarlane","year":"1990","unstructured":"McFarlane IG, Smith HM, Johnson PJ, et al. Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet. 1990;335:754\u2013757.","journal-title":"Lancet"},{"key":"2445_CR40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02063938","volume":"40","author":"AJ Czaja","year":"1995","unstructured":"Czaja AJ, Magrin S, Fabiano C, et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci. 1995;40:33\u201340.","journal-title":"Dig Dis Sci"},{"key":"2445_CR41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0065-2423(05)40004-9","volume":"40","author":"AJ Czaja","year":"2005","unstructured":"Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem. 2005;40:127\u2013164.","journal-title":"Adv Clin Chem"},{"key":"2445_CR42","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-010-1501-1","volume":"56","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci. 2011;56:545\u2013554.","journal-title":"Dig Dis Sci"},{"key":"2445_CR43","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929\u2013938.","journal-title":"J Hepatol"},{"key":"2445_CR44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169\u2013176.","journal-title":"Hepatology"},{"key":"2445_CR45","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1053\/gast.1997.v113.pm9247489","volume":"113","author":"DS Pratt","year":"1997","unstructured":"Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology. 1997;113:664\u2013668.","journal-title":"Gastroenterology"},{"key":"2445_CR46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1386-6346(02)00274-7","volume":"25","author":"N Okano","year":"2003","unstructured":"Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263\u2013270.","journal-title":"Hepatol Res"},{"key":"2445_CR47","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00000478-200404000-00006","volume":"28","author":"J Misdraji","year":"2004","unstructured":"Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol. 2004;28:471\u2013478.","journal-title":"Am J Surg Pathol"},{"key":"2445_CR48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/jcp.2005.029348","volume":"59","author":"H Hofer","year":"2006","unstructured":"Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006;59:246\u2013249.","journal-title":"J Clin Pathol"},{"key":"2445_CR49","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.humpath.2007.03.019","volume":"38","author":"Y Zen","year":"2007","unstructured":"Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol. 2007;38:1669\u20131675.","journal-title":"Hum Pathol"},{"key":"2445_CR50","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1111\/j.1572-0241.2002.06052.x","volume":"97","author":"R Singh","year":"2002","unstructured":"Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol. 2002;97:2670\u20132673.","journal-title":"Am J Gastroenterol"},{"key":"2445_CR51","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0022-3476(05)82892-6","volume":"116","author":"G Maggiore","year":"1990","unstructured":"Maggiore G, Porta G, Bernard O, et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr. 1990;116:280\u2013282.","journal-title":"J Pediatr"},{"key":"2445_CR52","first-page":"175","volume":"60","author":"N Latif","year":"2010","unstructured":"Latif N, Mehmood K. Risk factors for fulminant hepatic failure and their relation with outcome in children. J Pak Med Assoc. 2010;60:175\u2013178.","journal-title":"J Pak Med Assoc"},{"key":"2445_CR53","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/MEG.0b013e328353750c","volume":"24","author":"C Della Corte","year":"2012","unstructured":"Della Corte C, Sartorelli MR, Sindoni CD, et al. Autoimmune hepatitis in children: an overview of the disease focusing on current therapies. Eur J Gastroenterol Hepatol. 2012;24:739\u2013746.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2445_CR54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-2006-927280","volume":"45","author":"A Potthoff","year":"2007","unstructured":"Potthoff A, Deterding K, Trautwein C, et al. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol. 2007;45:15\u201319.","journal-title":"Z Gastroenterol"},{"key":"2445_CR55","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/lt.21088","volume":"13","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 2007;13:953\u2013955.","journal-title":"Liver Transpl"},{"key":"2445_CR56","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0041-1345(03)00591-8","volume":"35","author":"O Nunez-Martinez","year":"2003","unstructured":"Nunez-Martinez O, De la Cruz G, Salcedo M, et al. Liver transplantation for autoimmune hepatitis: fulminant versus chronic hepatitis presentation. Transpl Proc. 2003;35:1857\u20131858.","journal-title":"Transpl Proc"},{"key":"2445_CR57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-0032-1301733","volume":"33","author":"WM Lee","year":"2012","unstructured":"Lee WM. Acute liver failure. Semin Respir Crit Care Med. 2012;33:36\u201345.","journal-title":"Semin Respir Crit Care Med"},{"key":"2445_CR58","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1872-034X.2007.00125.x","volume":"37","author":"Y Miyake","year":"2007","unstructured":"Miyake Y, Iwasaki Y, Terada R, et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res. 2007;37:801\u2013805.","journal-title":"Hepatol Res"},{"key":"2445_CR59","first-page":"1233","volume":"52","author":"T Kanda","year":"2005","unstructured":"Kanda T, Yokosuka O, Hirasawa Y, et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology. 2005;52:1233\u20131235.","journal-title":"Hepatogastroenterology"},{"key":"2445_CR60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1478-3231.2011.02585.x","volume":"31","author":"IW Graziadei","year":"2011","unstructured":"Graziadei IW. The clinical challenges of acute on chronic liver failure. Liver Int. 2011;31:24\u201326.","journal-title":"Liver Int"},{"key":"2445_CR61","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.3748\/wjg.v11.i38.6069","volume":"11","author":"H Tanaka","year":"2005","unstructured":"Tanaka H, Tujioka H, Ueda H, et al. Autoimmune hepatitis triggered by acute hepatitis A. World J Gastroenterol. 2005;11:6069\u20136071.","journal-title":"World J Gastroenterol"},{"key":"2445_CR62","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0168-8278(95)80336-X","volume":"23","author":"HI Huppertz","year":"1995","unstructured":"Huppertz HI, Treichel U, Gassel AM, Jeschke R, Meyer zum Buschenfelde KH. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol. 1995;23:204\u2013208.","journal-title":"J Hepatol"},{"key":"2445_CR63","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0140-6736(97)06478-7","volume":"351","author":"N Kerkar","year":"1998","unstructured":"Kerkar N, Hadzic N, Davies ET, et al. De novo autoimmune hepatitis after liver transplantation. Lancet. 1998;351:409\u2013413.","journal-title":"Lancet"},{"key":"2445_CR64","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/BF01537282","volume":"34","author":"T Laskus","year":"1989","unstructured":"Laskus T, Slusarczyk J. Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig Dis Sci. 1989;34:1294\u20131297.","journal-title":"Dig Dis Sci"},{"key":"2445_CR65","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.TP.0000132328.33460.43","volume":"78","author":"A Miyagawa-Hayashino","year":"2004","unstructured":"Miyagawa-Hayashino A, Haga H, Egawa H, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation. 2004;78:128\u2013135.","journal-title":"Transplantation"},{"key":"2445_CR66","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0140-6736(91)92858-Y","volume":"337","author":"S Vento","year":"1991","unstructured":"Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183\u20131187.","journal-title":"Lancet"},{"key":"2445_CR67","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1007\/s10620-012-2179-3","volume":"57","author":"AJ Czaja","year":"2012","unstructured":"Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci. 2012;57:2248\u20132266.","journal-title":"Dig Dis Sci"},{"key":"2445_CR68","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00535-008-2254-x","volume":"43","author":"K Fujiwara","year":"2008","unstructured":"Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol. 2008;43:951\u2013958.","journal-title":"J Gastroenterol"},{"key":"2445_CR69","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1872-034X.2008.00347.x","volume":"38","author":"M Iwai","year":"2008","unstructured":"Iwai M, Jo M, Ishii M, Mori T, Harada Y. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol Res. 2008;38:784\u2013789.","journal-title":"Hepatol Res"},{"key":"2445_CR70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.dld.2009.04.009","volume":"42","author":"Y Miyake","year":"2010","unstructured":"Miyake Y, Iwasaki Y, Kobashi H, et al. Autoimmune hepatitis with acute presentation in Japan. Dig Liver Dis. 2010;42:51\u201354.","journal-title":"Dig Liver Dis"},{"key":"2445_CR71","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s10620-011-2017-z","volume":"57","author":"AJ Czaja","year":"2012","unstructured":"Czaja AJ. Autoantibody-negative autoimmune hepatitis. Dig Dis Sci. 2012;57:610\u2013624.","journal-title":"Dig Dis Sci"},{"key":"2445_CR72","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.1840040409","volume":"4","author":"AJ Czaja","year":"1984","unstructured":"Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984;4:622\u2013627.","journal-title":"Hepatology"},{"key":"2445_CR73","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/gast.1996.v110.pm8608895","volume":"110","author":"SK Roberts","year":"1996","unstructured":"Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848\u2013857.","journal-title":"Gastroenterology"},{"key":"2445_CR74","first-page":"360","volume":"55","author":"AJ Czaja","year":"1980","unstructured":"Czaja AJ, Wolf AM, Baggenstoss AH. Clinical assessment of cirrhosis in severe chronic active liver disease: specificity and sensitivity of physical and laboratory findings. Mayo Clin Proc. 1980;55:360\u2013364.","journal-title":"Mayo Clin Proc"},{"key":"2445_CR75","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.4049\/jimmunol.161.7.3527","volume":"161","author":"DG Doherty","year":"1998","unstructured":"Doherty DG, Penzotti JE, Koelle DM, et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol. 1998;161:3527\u20133535.","journal-title":"J Immunol"},{"key":"2445_CR76","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1089-3261(02)00018-1","volume":"6","author":"D Vergani","year":"2002","unstructured":"Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6:727\u2013737.","journal-title":"Clin Liver Dis"},{"key":"2445_CR77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474124.1.1.113","volume":"1","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113\u2013128.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2445_CR78","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0090-1229(88)90022-0","volume":"48","author":"P Paoli De","year":"1988","unstructured":"De Paoli P, Battistin S, Santini GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol. 1988;48:290\u2013296.","journal-title":"Clin Immunol Immunopathol"},{"key":"2445_CR79","first-page":"71","volume":"10","author":"DM Murasko","year":"1990","unstructured":"Murasko DM, Goonewardene IM. T-cell function in aging: mechanisms of decline. Annu Rev Gerontol Geriatr. 1990;10:71\u201396.","journal-title":"Annu Rev Gerontol Geriatr"},{"key":"2445_CR80","first-page":"26","volume":"18","author":"MS Currie","year":"1992","unstructured":"Currie MS. Immunosenescence. Compr Ther. 1992;18:26\u201334.","journal-title":"Compr Ther"},{"key":"2445_CR81","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/eji.1830221134","volume":"22","author":"R Schwab","year":"1992","unstructured":"Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol. 1992;22:2989\u20132993.","journal-title":"Eur J Immunol"},{"key":"2445_CR82","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3109\/07357909209024815","volume":"10","author":"A Ben-Yehuda","year":"1992","unstructured":"Ben-Yehuda A, Weksler ME. Immune senescence: mechanisms and clinical implications. Cancer Invest. 1992;10:525\u2013531.","journal-title":"Cancer Invest"},{"key":"2445_CR83","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.21074","volume":"43","author":"AJ Czaja","year":"2006","unstructured":"Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532\u2013538.","journal-title":"Hepatology"},{"key":"2445_CR84","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(68)92893-6","volume":"2","author":"MJ Rowley","year":"1968","unstructured":"Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet. 1968;2:24\u201326.","journal-title":"Lancet"},{"key":"2445_CR85","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/08916939108997112","volume":"8","author":"E Talor","year":"1991","unstructured":"Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity. 1991;8:245\u2013249.","journal-title":"Autoimmunity"},{"key":"2445_CR86","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/0016-5085(93)90157-8","volume":"105","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105:1502\u20131507.","journal-title":"Gastroenterology"},{"key":"2445_CR87","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hep.510250211","volume":"25","author":"AJ Czaja","year":"1997","unstructured":"Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25:317\u2013323.","journal-title":"Hepatology"},{"key":"2445_CR88","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jhep.2007.05.011","volume":"47","author":"W Bernal","year":"2007","unstructured":"Bernal W, Ma Y, Smith HM, et al. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol. 2007;47:664\u2013670.","journal-title":"J Hepatol"},{"key":"2445_CR89","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/hep.21828","volume":"46","author":"PS Leung","year":"2007","unstructured":"Leung PS, Rossaro L, Davis PA, et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology. 2007;46:1436\u20131442.","journal-title":"Hepatology"},{"key":"2445_CR90","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0168-8278(99)80096-8","volume":"30","author":"AJ Czaja","year":"1999","unstructured":"Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394\u2013401.","journal-title":"J Hepatol"},{"key":"2445_CR91","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/1744666X.2.1.33","volume":"2","author":"AJ Czaja","year":"2006","unstructured":"Czaja AJ. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev Clin Immunol. 2006;2:33\u201348.","journal-title":"Expert Rev Clin Immunol"},{"key":"2445_CR92","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/17474124.1.1.129","volume":"1","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gastroenterol Hepatol. 2007;1:129\u2013143.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2445_CR93","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cgh.2007.05.031","volume":"5","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol. 2007;5:898\u2013907.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2445_CR94","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/0016-5085(93)91081-R","volume":"105","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824\u20131832.","journal-title":"Gastroenterology"},{"key":"2445_CR95","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/hep.510260229","volume":"26","author":"AJ Czaja","year":"1997","unstructured":"Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology. 1997;26:459\u2013466.","journal-title":"Hepatology"},{"key":"2445_CR96","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931\u2013939.","journal-title":"Hepatology"},{"key":"2445_CR97","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD, et al. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193\u20132213.","journal-title":"Hepatology"},{"key":"2445_CR98","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1572-0241.2007.01609.x","volume":"103","author":"MA Worns","year":"2008","unstructured":"Worns MA, Teufel A, Kanzler S, et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol. 2008;103:138\u2013146.","journal-title":"Am J Gastroenterol"},{"key":"2445_CR99","doi-asserted-by":"crossref","unstructured":"Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int. 2012.","DOI":"10.1111\/j.1478-3231.2012.02790.x"},{"key":"2445_CR100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s12072-010-9217-z","volume":"5","author":"J Lal","year":"2011","unstructured":"Lal J, Thapa BR, Rawal P, Ratho RK, Singh K. Predictors of outcome in acute-on-chronic liver failure in children. Hepatol Int. 2011;5:693\u2013697.","journal-title":"Hepatol Int"},{"key":"2445_CR101","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1053\/jhep.2001.24562","volume":"33","author":"L Fainboim","year":"2001","unstructured":"Fainboim L, Canero Velasco MC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology. 2001;33:1512\u20131517.","journal-title":"Hepatology"},{"key":"2445_CR102","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000082253","volume":"70","author":"F Grunhage","year":"2004","unstructured":"Grunhage F, Spengler U, Fischer HP, Sauerbruch T. Autoimmune hepatitis\u2013sequel of a relapsing hepatitis A in a 75-year-old woman. Digestion. 2004;70:187\u2013191.","journal-title":"Digestion"},{"key":"2445_CR103","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1665-2681(19)31878-2","volume":"7","author":"F Tabak","year":"2008","unstructured":"Tabak F, Ozdemir F, Tabak O, et al. Autoimmune hepatitis induced by the prolonged hepatitis A virus infection. Ann Hepatol. 2008;7:177\u2013179.","journal-title":"Ann Hepatol"},{"key":"2445_CR104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(87)93051-0","volume":"2","author":"DA Robertson","year":"1987","unstructured":"Robertson DA, Zhang SL, Guy EC, Wright R. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet. 1987;2:9\u201311.","journal-title":"Lancet"},{"key":"2445_CR105","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(89)92836-5","volume":"1","author":"KH Kalland","year":"1989","unstructured":"Kalland KH, Endresen C, Haukenes G, Schrumpf E. Measles-specific nucleotide sequences and autoimmune chronic active hepatitis. Lancet. 1989;1:1390\u20131391.","journal-title":"Lancet"},{"key":"2445_CR106","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","volume":"51","author":"E Bjornsson","year":"2010","unstructured":"Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040\u20132048.","journal-title":"Hepatology"},{"key":"2445_CR107","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/0016-5085(92)90786-X","volume":"102","author":"M Shindo","year":"1992","unstructured":"Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology. 1992;102:1406\u20131408.","journal-title":"Gastroenterology"},{"key":"2445_CR108","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/0003-4819-116-1-51","volume":"116","author":"T Papo","year":"1992","unstructured":"Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med. 1992;116:51\u201353.","journal-title":"Ann Intern Med"},{"key":"2445_CR109","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/0016-5085(95)90139-6","volume":"108","author":"L Garcia-Buey","year":"1995","unstructured":"Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology. 1995;108:1770\u20131777.","journal-title":"Gastroenterology"},{"key":"2445_CR110","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.dld.2011.02.014","volume":"43","author":"S Yasui","year":"2011","unstructured":"Yasui S, Fujiwara K, Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis. 2011;43:666\u2013667.","journal-title":"Dig Liver Dis"},{"key":"2445_CR111","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","volume":"44","author":"R Poupon","year":"2006","unstructured":"Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006;44:85\u201390.","journal-title":"Hepatology"},{"key":"2445_CR112","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1478-3231.2007.01538.x","volume":"27","author":"AA Gossard","year":"2007","unstructured":"Gossard AA, Lindor KD. Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int. 2007;27:1086\u20131090.","journal-title":"Liver Int"},{"key":"2445_CR113","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/lt.21796","volume":"15","author":"AJ Montano-Loza","year":"2009","unstructured":"Montano-Loza AJ, Mason AL, Ma M, et al. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15:1254\u20131261.","journal-title":"Liver Transpl"},{"key":"2445_CR114","first-page":"79","volume":"1","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ. Recurrent autoimmune hepatitis after liver transplantation. Ann Gastroenterol Hepatol. 2010;1:79\u201389.","journal-title":"Ann Gastroenterol Hepatol"},{"key":"2445_CR115","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/hep.20703","volume":"41","author":"J Polson","year":"2005","unstructured":"Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179\u20131197.","journal-title":"Hepatology"},{"key":"2445_CR116","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.25551","volume":"55","author":"WM Lee","year":"2012","unstructured":"Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55:965\u2013967.","journal-title":"Hepatology"},{"key":"2445_CR117","first-page":"282","volume":"3","author":"C Trey","year":"1970","unstructured":"Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282\u2013298.","journal-title":"Prog Liver Dis"},{"key":"2445_CR118","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0140-6736(93)91818-7","volume":"342","author":"JG O\u2019Grady","year":"1993","unstructured":"O\u2019Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273\u2013275.","journal-title":"Lancet"},{"key":"2445_CR119","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1440-1746.1999.01905.x","volume":"14","author":"BN Tandon","year":"1999","unstructured":"Tandon BN, Bernauau J, O\u2019Grady J, et al. Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. J Gastroenterol Hepatol. 1999;14:403\u2013404.","journal-title":"J Gastroenterol Hepatol"},{"key":"2445_CR120","first-page":"261","volume":"8","author":"Y Wang","year":"2000","unstructured":"Wang Y, Chen Y, Gu C, Jiang L, Xiang D. Reevaluation of the nomenclature and diagnostic criteria in 477 patients with severe hepatitis. Zhonghua Gan Zang Bing Za Zhi. 2000;8:261\u2013263.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"2445_CR121","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/j.1440-1746.2006.04362.x","volume":"22","author":"Q Liu","year":"2007","unstructured":"Liu Q, Liu Z, Wang T, et al. Characteristics of acute and sub-acute liver failure in China: nomination, classification and interval. J Gastroenterol Hepatol. 2007;22:2101\u20132106.","journal-title":"J Gastroenterol Hepatol"},{"key":"2445_CR122","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1872-034X.2011.00860.x","volume":"41","author":"S Mochida","year":"2011","unstructured":"Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res. 2011;41:805\u2013812.","journal-title":"Hepatol Res"},{"key":"2445_CR123","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","volume":"18","author":"PJ Johnson","year":"1993","unstructured":"Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998\u20131005.","journal-title":"Hepatology"},{"key":"2445_CR124","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1440-1746.1991.tb01458.x","volume":"6","author":"Y Takahashi","year":"1991","unstructured":"Takahashi Y, Shimizu M. Aetiology and prognosis of fulminant viral hepatitis in Japan: a multicentre study. The Study Group of Fulminant Hepatitis. J Gastroenterol Hepatol. 1991;6:159\u2013164.","journal-title":"J Gastroenterol Hepatol"},{"key":"2445_CR125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/hep.1840060222","volume":"6","author":"AE Gimson","year":"1986","unstructured":"Gimson AE, O\u2019Grady J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure: clinical, serological and histological features. Hepatology. 1986;6:288\u2013294.","journal-title":"Hepatology"},{"key":"2445_CR126","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2008-1040593","volume":"6","author":"J Bernuau","year":"1986","unstructured":"Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis. 1986;6:97\u2013106.","journal-title":"Semin Liver Dis"},{"key":"2445_CR127","doi-asserted-by":"crossref","unstructured":"Tandon BN, Joshi YK, Krishnamurthy L, Tandon HD. Subacute hepatic failure; is it a distinct entity? J Clin Gastroenterol. 1982;4:343\u2013346.","DOI":"10.1097\/00004836-198208000-00010"},{"key":"2445_CR128","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2036.2012.05097.x","volume":"35","author":"KA Wlodzimirow","year":"2012","unstructured":"Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. Systematic review: acute liver failure\u2014one disease, more than 40 definitions. Aliment Pharmacol Ther. 2012;35:1245\u20131256.","journal-title":"Aliment Pharmacol Ther"},{"key":"2445_CR129","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1478-3231.2011.02524.x","volume":"31","author":"K Fujiwara","year":"2011","unstructured":"Fujiwara K, Yasui S, Tawada A, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis. Liver Int. 2011;31:1013\u20131020.","journal-title":"Liver Int"},{"key":"2445_CR130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.MPG.0000158524.30294.E2","volume":"40","author":"WS Lee","year":"2005","unstructured":"Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United kingdom. J Pediatr Gastroenterol Nutr. 2005;40:575\u2013581.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2445_CR131","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1440-1746.2008.05402.x","volume":"23","author":"A Hiramatsu","year":"2008","unstructured":"Hiramatsu A, Takahashi S, Aikata H, et al. Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center. J Gastroenterol Hepatol. 2008;23:1216\u20131222.","journal-title":"J Gastroenterol Hepatol"},{"key":"2445_CR132","first-page":"163","volume":"6","author":"AO Shakil","year":"2000","unstructured":"Shakil AO, Kramer D, Mazariegos GV, Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000;6:163\u2013169.","journal-title":"Liver Transpl"},{"key":"2445_CR133","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jpeds.2009.06.005","volume":"155","author":"MR Narkewicz","year":"2009","unstructured":"Narkewicz MR, Dell Olio D, Karpen SJ, et al. Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement. J Pediatr. 2009;155:801\u2013806.","journal-title":"J Pediatr"},{"key":"2445_CR134","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jamcollsurg.2007.08.018","volume":"206","author":"T Ikegami","year":"2008","unstructured":"Ikegami T, Taketomi A, Soejima Y, et al. Living donor liver transplantation for acute liver failure: a 10-year experience in a single center. J Am Coll Surg. 2008;206:412\u2013418.","journal-title":"J Am Coll Surg"},{"key":"2445_CR135","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1007\/s10620-011-1769-9","volume":"56","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011;56:3421\u20133438.","journal-title":"Dig Dis Sci"},{"key":"2445_CR136","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/hep.22513","volume":"48","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540\u20131548.","journal-title":"Hepatology"},{"key":"2445_CR137","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0016-5085(89)90081-4","volume":"97","author":"JG O\u2019Grady","year":"1989","unstructured":"O\u2019Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439\u2013445.","journal-title":"Gastroenterology"},{"key":"2445_CR138","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00261-008-9485-4","volume":"35","author":"VA Sahni","year":"2010","unstructured":"Sahni VA, Raghunathan G, Mearadji B, et al. Autoimmune hepatitis: CT and MR imaging features with histopathological correlation. Abdom Imaging. 2010;35:75\u201384.","journal-title":"Abdom Imaging"},{"key":"2445_CR139","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ejrad.2008.07.020","volume":"72","author":"B Cakir","year":"2009","unstructured":"Cakir B, Kirbas I, Demirhan B, et al. Fulminant hepatic failure in children: etiology, histopathology and MDCT findings. Eur J Radiol. 2009;72:327\u2013334.","journal-title":"Eur J Radiol"},{"key":"2445_CR140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1872-034X.2011.00892.x","volume":"42","author":"S Yasui","year":"2012","unstructured":"Yasui S, Fujiwara K, Okitsu K, et al. Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure. Hepatol Res. 2012;42:42\u201350.","journal-title":"Hepatol Res"},{"key":"2445_CR141","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-0028-1109146","volume":"47","author":"S Heringlake","year":"2009","unstructured":"Heringlake S, Schutte A, Flemming P, et al. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol. 2009;47:417\u2013423.","journal-title":"Z Gastroenterol"},{"key":"2445_CR142","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12185-010-0557-1","volume":"91","author":"AM Wehbe","year":"2010","unstructured":"Wehbe AM, Johannsson B, Raife TJ, et al. Severe autoimmune neutropenia associated with acute autoimmune hepatitis. Int J Hematol. 2010;91:673\u2013678.","journal-title":"Int J Hematol"},{"key":"2445_CR143","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1386-6346(01)00109-7","volume":"21","author":"M Abe","year":"2001","unstructured":"Abe M, Hiasa Y, Masumoto T, et al. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatol Res. 2001;21:213\u2013219.","journal-title":"Hepatol Res"},{"key":"2445_CR144","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.1111\/j.1872-034X.2007.00234.x","volume":"37","author":"M Kage","year":"2007","unstructured":"Kage M. Pathology of autoimmune liver diseases in children. Hepatol Res. 2007;37:S502\u2013S508.","journal-title":"Hepatol Res"},{"key":"2445_CR145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cgh.2006.10.011","volume":"5","author":"M Abe","year":"2007","unstructured":"Abe M, Onji M, Kawai-Ninomiya K, et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol. 2007;5:255\u2013258.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2445_CR146","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep.23042","volume":"50","author":"AD Yeoman","year":"2009","unstructured":"Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology. 2009;50:538\u2013545.","journal-title":"Hepatology"},{"key":"2445_CR147","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1148\/radiology.198.1.8539386","volume":"198","author":"T Murakami","year":"1996","unstructured":"Murakami T, Baron RL, Peterson MS. Liver necrosis and regeneration after fulminant hepatitis: pathologic correlation with CT and MR findings. Radiology. 1996;198:239\u2013242.","journal-title":"Radiology"},{"key":"2445_CR148","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2214\/ajr.183.6.01831573","volume":"183","author":"A Qayyum","year":"2004","unstructured":"Qayyum A, Graser A, Westphalen A, et al. CT of benign hypervascular liver nodules in autoimmune hepatitis. AJR. 2004;183:1573\u20131576.","journal-title":"AJR"},{"key":"2445_CR149","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0528.2002.017401.x","volume":"174","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev. 2000;174:250\u2013259.","journal-title":"Immunol Rev"},{"key":"2445_CR150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cgh.2007.12.048","volume":"6","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379\u2013388.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2445_CR151","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/j.1572-0241.2002.06019.x","volume":"97","author":"KJ Hurlburt","year":"2002","unstructured":"Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402\u20132407.","journal-title":"Am J Gastroenterol"},{"key":"2445_CR152","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0168-8278(02)00182-4","volume":"37","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol. 2002;37:302\u2013308.","journal-title":"J Hepatol"},{"key":"2445_CR153","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0198-8859(94)90008-6","volume":"41","author":"L Fainboim","year":"1994","unstructured":"Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol. 1994;41:146\u2013150.","journal-title":"Hum Immunol"},{"key":"2445_CR154","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0198-8859(00)00234-2","volume":"62","author":"AC Goldberg","year":"2001","unstructured":"Goldberg AC, Bittencourt PL, Mougin B, et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol. 2001;62:165\u2013169.","journal-title":"Hum Immunol"},{"key":"2445_CR155","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/hep.1840120609","volume":"12","author":"T Seki","year":"1990","unstructured":"Seki T, Kiyosawa K, Inoko H, Ota M. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology. 1990;12:1300\u20131304.","journal-title":"Hepatology"},{"key":"2445_CR156","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0016-5085(92)90041-V","volume":"103","author":"T Seki","year":"1992","unstructured":"Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology. 1992;103:1041\u20131047.","journal-title":"Gastroenterology"},{"key":"2445_CR157","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.510310110","volume":"31","author":"K Agarwal","year":"2000","unstructured":"Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology. 2000;31:49\u201353.","journal-title":"Hepatology"},{"key":"2445_CR158","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/hep.510300412","volume":"30","author":"S Cookson","year":"1999","unstructured":"Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851\u2013856.","journal-title":"Hepatology"},{"key":"2445_CR159","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0016-5085(99)70458-0","volume":"117","author":"AJ Czaja","year":"1999","unstructured":"Czaja AJ, Cookson S, Constantini PK, et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999;117:645\u2013652.","journal-title":"Gastroenterology"},{"key":"2445_CR160","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1572-0241.2005.41053.x","volume":"100","author":"A Hiraide","year":"2005","unstructured":"Hiraide A, Imazeki F, Yokosuka O, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005;100:1322\u20131329.","journal-title":"Am J Gastroenterol"},{"key":"2445_CR161","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1399-0039.2006.00794.x","volume":"69","author":"K Agarwal","year":"2007","unstructured":"Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007;69:227\u2013235.","journal-title":"Tissue Antigens"},{"key":"2445_CR162","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/hep.21518","volume":"45","author":"S Yokosawa","year":"2007","unstructured":"Yokosawa S, Yoshizawa K, Ota M, et al. A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1. Hepatology. 2007;45:384\u2013390.","journal-title":"Hepatology"},{"key":"2445_CR163","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2559.2011.03790.x","volume":"58","author":"K Fujiwara","year":"2011","unstructured":"Fujiwara K, Nakano M, Yasui S, et al. Advanced histology and impaired liver regeneration are associated with disease severity in acute-onset autoimmune hepatitis. Histopathology. 2011;58:693\u2013704.","journal-title":"Histopathology"},{"key":"2445_CR164","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jhep.2006.08.022","volume":"46","author":"A Warren","year":"2007","unstructured":"Warren A, Bertolino P, Benseler V, et al. Marked changes of the hepatic sinusoid in a transgenic mouse model of acute immune-mediated hepatitis. J Hepatol. 2007;46:239\u2013246.","journal-title":"J Hepatol"},{"key":"2445_CR165","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.21787","volume":"46","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138\u20131145.","journal-title":"Hepatology"},{"key":"2445_CR166","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/gut.2007.131730","volume":"57","author":"J Neuberger","year":"2008","unstructured":"Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut. 2008;57:252\u2013257.","journal-title":"Gut"},{"key":"2445_CR167","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.24141","volume":"53","author":"AD Yeoman","year":"2011","unstructured":"Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 2011;53:926\u2013934.","journal-title":"Hepatology"},{"key":"2445_CR168","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0016-5085(88)90503-3","volume":"95","author":"AJ Czaja","year":"1988","unstructured":"Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448\u2013453.","journal-title":"Gastroenterology"},{"key":"2445_CR169","doi-asserted-by":"crossref","unstructured":"Kumar R, Shalimar, Sharma H, et al. Prospective derivation and validation of early dynamic model for predicting outcome in patients with acute liver failure. Gut. 2012;61:1068\u20131075.","DOI":"10.1136\/gutjnl-2011-301762"},{"key":"2445_CR170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1872-034X.2011.00902.x","volume":"42","author":"T Naiki","year":"2012","unstructured":"Naiki T, Nakayama N, Mochida S, et al. Novel scoring system as a useful model to predict the outcome of patients with acute liver failure: application to indication criteria for liver transplantation. Hepatol Res. 2012;42:68\u201375.","journal-title":"Hepatol Res"},{"key":"2445_CR171","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","volume":"139","author":"MP Manns","year":"2010","unstructured":"Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198\u20131206.","journal-title":"Gastroenterology"},{"key":"2445_CR172","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/0016-5085(87)90454-9","volume":"93","author":"JS Hyams","year":"1987","unstructured":"Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology. 1987;93:890\u2013893.","journal-title":"Gastroenterology"},{"key":"2445_CR173","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00004836-199312000-00012","volume":"17","author":"JL Person","year":"1993","unstructured":"Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol. 1993;17:317\u2013320.","journal-title":"J Clin Gastroenterol"},{"key":"2445_CR174","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","volume":"21","author":"KE Sherman","year":"1994","unstructured":"Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol. 1994;21:1040\u20131047.","journal-title":"J Hepatol"},{"key":"2445_CR175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/gut.36.3.459","volume":"36","author":"LD Jackson","year":"1995","unstructured":"Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut. 1995;36:459\u2013461.","journal-title":"Gut"},{"key":"2445_CR176","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1572-0241.1999.00807.x","volume":"94","author":"NF Fernandes","year":"1999","unstructured":"Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999;94:241\u2013248.","journal-title":"Am J Gastroenterol"},{"key":"2445_CR177","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","volume":"46","author":"R Malekzadeh","year":"2001","unstructured":"Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46:1321\u20131327.","journal-title":"Dig Dis Sci"},{"key":"2445_CR178","first-page":"771","volume":"90","author":"DH Thiel Van","year":"1995","unstructured":"Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771\u2013776.","journal-title":"Am J Gastroenterol"},{"key":"2445_CR179","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","volume":"38","author":"BA Aqel","year":"2004","unstructured":"Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004;38:805\u2013809.","journal-title":"J Clin Gastroenterol"},{"key":"2445_CR180","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3748\/wjg.v13.i26.3610","volume":"13","author":"FS Larsen","year":"2007","unstructured":"Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol. 2007;13:3232\u20133236.","journal-title":"World J Gastroenterol"},{"key":"2445_CR181","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2036.2011.04749.x","volume":"34","author":"MM Tannous","year":"2011","unstructured":"Tannous MM, Cheng J, Muniyappa K, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011;34:405\u2013407.","journal-title":"Aliment Pharmacol Ther"},{"key":"2445_CR182","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","volume":"103","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103:3063\u20133070.","journal-title":"Am J Gastroenterol"},{"key":"2445_CR183","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","volume":"24","author":"K Sharzehi","year":"2010","unstructured":"Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24:588\u2013592.","journal-title":"Can J Gastroenterol"},{"key":"2445_CR184","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04727.x","volume":"34","author":"AM Baven-Pronk","year":"2011","unstructured":"Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34:335\u2013343.","journal-title":"Aliment Pharmacol Ther"},{"key":"2445_CR185","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1007\/s10620-012-2151-2","volume":"57","author":"AJ Czaja","year":"2012","unstructured":"Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci. 2012;57:1996\u20132010.","journal-title":"Dig Dis Sci"},{"key":"2445_CR186","unstructured":"Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-I. Inflamm Allergy Drug Targets. 2012;11:337\u2013350."},{"key":"2445_CR187","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hep.1840150208","volume":"15","author":"L Sanchez-Urdazpal","year":"1992","unstructured":"Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15:215\u2013221.","journal-title":"Hepatology"},{"key":"2445_CR188","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1399-0012.2004.00117.x","volume":"18","author":"A Vogel","year":"2004","unstructured":"Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant. 2004;18:62\u201369.","journal-title":"Clin Transplant"},{"key":"2445_CR189","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/lt.21181","volume":"13","author":"TJ Cross","year":"2007","unstructured":"Cross TJ, Antoniades CG, Muiesan P, et al. Liver transplantation in patients over 60 and 65\u00a0years: an evaluation of long-term outcomes and survival. Liver Transpl. 2007;13:1382\u20131388.","journal-title":"Liver Transpl"},{"key":"2445_CR190","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","volume":"16","author":"WH Summerskill","year":"1975","unstructured":"Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16:876\u2013883.","journal-title":"Gut"},{"key":"2445_CR191","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14740338.7.3.319","volume":"7","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319\u2013333.","journal-title":"Expert Opin Drug Saf"},{"key":"2445_CR192","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.gastro.2010.04.053","volume":"139","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology. 2010;139:58\u201372.","journal-title":"Gastroenterology"},{"key":"2445_CR193","first-page":"221","volume":"8","author":"SW Schalm","year":"1976","unstructured":"Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res. 1976;8:221\u2013227.","journal-title":"Ann Clin Res"},{"key":"2445_CR194","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.2174\/138161211798157568","volume":"17","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des. 2011;17:3120\u20133140.","journal-title":"Curr Pharm Des"},{"key":"2445_CR195","doi-asserted-by":"crossref","unstructured":"Czaja AJ. Drug choices in autoimmune hepatitis: Part B\u2014non-steroids. Expert Rev Gastroenterol Hepatol. 2012;6:617\u2013635.","DOI":"10.1586\/egh.12.38"},{"key":"2445_CR196","doi-asserted-by":"crossref","unstructured":"Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012;36:691\u2013707.","DOI":"10.1111\/apt.12042"},{"key":"2445_CR197","doi-asserted-by":"crossref","unstructured":"Czaja AJ. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol. 2012;26:615\u2013620.","DOI":"10.1155\/2012\/512132"},{"key":"2445_CR198","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.mcg.0000177260.72692.e8","volume":"39","author":"AJ Czaja","year":"2005","unstructured":"Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol. 2005;39:819\u2013825.","journal-title":"J Clin Gastroenterol"},{"key":"2445_CR199","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0168-8278(00)80271-8","volume":"33","author":"PD Richardson","year":"2000","unstructured":"Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol. 2000;33:371\u2013375.","journal-title":"J Hepatol"},{"key":"2445_CR200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jhep.2009.03.011","volume":"51","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree. J Hepatol. 2009;51:8\u201310.","journal-title":"J Hepatol"},{"key":"2445_CR201","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1053\/gast.2000.0010000001","volume":"119","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000;119:1312\u20131316.","journal-title":"Gastroenterology"},{"key":"2445_CR202","doi-asserted-by":"crossref","unstructured":"Czaja AJ. Drug choices in autoimmune hepatitis: Part A\u2014steroids. Expert Rev Gastroenterol Hepatol. 2012;6:603\u2013615.","DOI":"10.1586\/egh.12.40"},{"key":"2445_CR203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0162-3109(00)00186-7","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC. Immunosuppressive drugs: the first 50\u00a0years and a glance forward. Immunopharmacology. 2000;47:63\u201383.","journal-title":"Immunopharmacology"},{"key":"2445_CR204","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61\u201398.","journal-title":"Clin Pharmacokinet"},{"key":"2445_CR205","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0016-5085(77)80209-6","volume":"72","author":"SW Schalm","year":"1977","unstructured":"Schalm SW, Summerskill WH, Go VL. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology. 1977;72:910\u2013913.","journal-title":"Gastroenterology"},{"key":"2445_CR206","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/gut.19.12.1131","volume":"19","author":"M Uribe","year":"1978","unstructured":"Uribe M, Schalm SW, Summerskill WH, Go VL. Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. Gut. 1978;19:1131\u20131135.","journal-title":"Gut"},{"key":"2445_CR207","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-197904030-00005","volume":"4","author":"M Uribe","year":"1979","unstructured":"Uribe M, Go VL. Corticosteroid pharmacokinetics in liver disease. Clin Pharmacokinet. 1979;4:233\u2013240.","journal-title":"Clin Pharmacokinet"},{"key":"2445_CR208","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2165\/00003088-198207050-00005","volume":"7","author":"M Uribe","year":"1982","unstructured":"Uribe M, Summerskill WH, Go VL. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease. Clin Pharmacokinet. 1982;7:452\u2013459.","journal-title":"Clin Pharmacokinet"},{"key":"2445_CR209","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/bdd.2510150208","volume":"15","author":"V Garg","year":"1994","unstructured":"Garg V, Jusko WJ. Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm Drug Dispos. 1994;15:163\u2013172.","journal-title":"Biopharm Drug Dispos"},{"key":"2445_CR210","unstructured":"Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm Allergy Drug Targets. 2012;11:351\u2013363."},{"key":"2445_CR211","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1007\/s10620-009-1122-8","volume":"55","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci. 2010;55:2712\u20132726.","journal-title":"Dig Dis Sci"},{"key":"2445_CR212","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.transproceed.2007.02.030","volume":"39","author":"H Khalaf","year":"2007","unstructured":"Khalaf H, Mourad W, El-Sheikh Y, et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transpl Proc. 2007;39:1166\u20131170.","journal-title":"Transpl Proc"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2445-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-012-2445-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2445-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T09:24:28Z","timestamp":1687771468000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-012-2445-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,23]]},"references-count":212,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["2445"],"URL":"https:\/\/doi.org\/10.1007\/s10620-012-2445-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,23]]}}}